Introduction
============

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older individuals. Single nucleotide polymorphisms (SNPs) in at least 34 loci influence the risk for AMD \[[@r1]\], and the mechanisms by which these variants influence AMD are still being elucidated. Although some AMD-risk SNPs change the coding region of genes, most reside outside coding regions, suggesting potential effects in regulating the expression of linked genes \[[@r2],[@r3]\]. A set of closely linked SNPs on chromosome 10q26 is of special interest since this chromosome has more influence on the risk for AMD than any other AMD region \[[@r1],[@r4]-[@r7]\]; however, which gene in the region confers the risk remains unclear \[[@r5],[@r8]-[@r10]\]. Three genes are within 100 kilobase pairs (kb) of the SNPs associated with AMD. From the centromeric to telomeric ends of this region, the genes are *pleckstrin homology domain-containing family A member 1* (*PLEKHA1*; gene ID: 59338, OMIM: [607772](https://www.ncbi.nlm.nih.gov/omim/?term=607772)), *age-related maculopathy-2* (*ARMS2*; gene ID: 387715, OMIM: [611313](https://www.ncbi.nlm.nih.gov/omim/?term=611313)), and *high temperature requirement protein A1* (*HTRA1*; gene ID: 5654, OMIM: [602194](https://www.ncbi.nlm.nih.gov/omim/?term=602194)). It is even conceivable that a more distant gene actually confers the risk for AMD.

We searched for associations between AMD-risk SNPs in the 10q26 region and the expression of closely linked genes. We also looked for open chromatin in the region in RPE cells and transcription factor binding sites in the open chromatin since such regions often correspond with regions that regulate transcription.

Methods
=======

Linkage disequilibrium analysis
-------------------------------

Using the online tools [HaploReg](http://www.broadinstitute.org/mammals/haploreg/haploreg.php) and [LDlink](https://analysistools.nci.nih.gov/LDlink), SNPs associated with AMD and other variants were placed in a haplotype block using Query SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) and the linkage disequilibrium inclusion criterion r^2^ ≥0.8 \[[@r11],[@r12]\] in the 1000 Genome European population.

Transcriptome analysis
----------------------

The GTEx database allows one to search for relationships between human genotypes and gene expression in specific tissues \[[@r13],[@r14]\]. At the time of this analysis (January--October 2016), the GTEx project V6p ([GtexPortal](http://www.gtexportal.org/home/)) contained genotypes from 449 human adult donors and whole genome transcription data from up to 53 tissues from an overlapping set of 544 donors. Transcript levels of *PLEKHA1, ARMS2*, and *HTRA1* were included. The steady-state mRNA level is measured as reads per kilobase of transcript per million mapped reads (RPKM). RPKM are normalized according to the number of sequencing reads and the read lengths. RPKM below 1 indicate levels of mRNA expression that are difficult to distinguish from background noise.

Association between genetic variants and mRNA expression
--------------------------------------------------------

We searched for expression quantitative trait loci (eQTLs) in the chromosome 10q26 region by looking for correlations between SNP alleles and the expression of genes using the "Test your own eQTLs" option in the GTEx portal Version 6. The mRNA levels are expressed as rank normalized gene expression \[[@r15]\]. The effect size of an eQTL is the change in the value of the standardized gene expression level with each extra copy of the alternative (ALT) allele relative to the reference allele, conditional to all other adjustments (gender, probabilistic estimation of expression residuals factors, genotype principal components, and genotyping platforms). Because the gene expression levels of tissues have been transformed to a standard normal distribution (mean of 0 and standard deviation of 1), the effect size is also equivalent to the change in the population standard deviation; that is, an effect size of 0.2 means a change in 0.2 standard deviations from the baseline level with both reference alleles. The effect size provides the variation in the strength of expression with positive numbers indicating higher mRNA levels in samples from people with the minor allele compared to those with the major allele, and negative numbers indicating lower mRNA levels in samples with the minor allele. For the eQTL analysis, selected tissues were those for which high-quality mRNA results were available in at least 70 genotyped donors.

Search for open chromatin and transcription factor binding sites
----------------------------------------------------------------

We used the Encyclopedia of DNA Elements ([ENCODE](https://www.encodeproject.org/)) to search for DNase I sensitive sites; this database has results from more than 125 cell types, including primary cultures of RPE. We used three online programs that predict transcription factor binding sites: [HOMER](http://homer.salk.edu/homer/), [PROMO](http://alggen.lsi.upc.es/), and [RegulomeDB](http://www.regulomedb.org). The consensus binding sequences are from [JASPAR](http://jaspar.genereg.net/).

Statistical analysis
--------------------

The GTEx consortium database has precalculated nominal eQTL p values for every human gene and all the informative SNPs analyzed. The p values for each SNP-gene pair were calculated using a two-tailed *t* test as described at that site ([GtexPortal](http://www.gtexportal.org/home/documentationPage)). We considered associations statistically significant when the p value was less than 0.05. In some cases, as stated in the text, we made adjustments for the multiple analyses.

Results
=======

SNPs that define the AMD-risk haplotype in 10q26
------------------------------------------------

There are ten SNPs in a 17-kb region within 10q26 for which published data indicate strong associations of alleles with risk for AMD ([Table 1](#t1){ref-type="table"} and [Figure 1](#f1){ref-type="fig"}) \[[@r1],[@r16]-[@r39]\]. One of the SNPs, [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924), changes the *ARMS2* coding sequence (G versus T, Ala69Ser). The other nine SNPs are in strong linkage disequilibrium with [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924), and each has a correlation coefficient r^2^ ≥0.89 with [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924). Of these nine SNPs, [rs3750846](https://www.ncbi.nlm.nih.gov/snp/?term=rs3750846),[rs3750847](https://www.ncbi.nlm.nih.gov/snp/?term=%20rs3750847), and [rs3750848](https://www.ncbi.nlm.nih.gov/snp/?term=rs3750848) are in the only *ARMS2* intron, [rs3793917](https://www.ncbi.nlm.nih.gov/snp/?term=rs3793917) and [rs11200638](https://www.ncbi.nlm.nih.gov/snp/?term=rs11200638) are located in the *HTRA1* promoter region, [rs1049331](https://www.ncbi.nlm.nih.gov/snp/?term=rs1049331) and [rs2293870](https://www.ncbi.nlm.nih.gov/snp/?term=rs2293870) are synonymous variations in the *HTRA1* coding region, and [rs2284665](https://www.ncbi.nlm.nih.gov/snp/?term=rs2284665) and [rs932275](https://www.ncbi.nlm.nih.gov/snp/?term=rs932275) are in the first *HTRA1* intron. We considered the set of alleles of these ten SNPs, all from published studies showing association with elevated risk for AMD, as a presumed haplotype that we refer to as the "high-AMD-risk" haplotype ([Table 1](#t1){ref-type="table"}). Although data from all ten SNPs are in the GTEx database, we used [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) as the reference SNP because it is the most commonly evaluated SNP in studies of AMD \[[@r16]-[@r28]\]. The HaploReg and LDlink websites indicate that the haplotype defined by the ten SNPs includes an additional 24 polymorphisms (21 SNPs and three insertion-deletion polymorphisms) extending across a region of about 30 kb. Many of these 24 additional polymorphisms were not specifically evaluated in most previous genetic evaluations of AMD, but they likely have some association with risk for AMD because they have strong allelic correlations with [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924), with some having perfect correlations (i.e., r^2^ = 1; [Table 1](#t1){ref-type="table"}). Of these 24 additional polymorphisms, 15 are included in the GTEx database. The present analysis of eQTLs (SNP-gene expression correlations) concentrated on the 25 SNPs in the GTEx database, comprising the ten that have been reported to be associated with risk for AMD and the 15 in strong linkage disequilibrium with those ten. We focused especially on the reference SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) because the strong linkage disequilibrium of the other SNPs with the reference SNP meant that results from any of them would approximately predict the results from the others. The present studies of the other SNPs in the haplotype confirmed that prediction.

###### The 34 polymorphisms in linkage disequilibrium that form an AMD-associated haplotype block.

  **SNP**       **Chr 10 position (GPCh37)**   **REF/ALT Allele**   **r^2^ LDlink/ HaploReg**   **D\' LDlink/ HaploReg**   **AMD References**
  ------------- ------------------------------ -------------------- --------------------------- -------------------------- ---------------------------------------------------------
  rs61871744    124,203,787                    T/C                  0.96/0.94                   0.99/0.99                   
  rs59616332    124,208,562                    ATAAAC/-             0.96/NA                     0.99/NA                     
  rs11200630    124,209,684                    T/C                  0.99/0.98                   1/0.99                      
  rs61871745    124,210,369                    G/A                  0.99/0.98                   1/0.99                      
  rs11200632    124,211,536                    A/G                  0.99/0.99                   1/1                         
  rs11200633    124,211,596                    C/T                  0.99/0.98                   1/1                         
  rs61871746    124,212,913                    T/C                  1/1                         1/1                         
  rs61871747    124,213,046                    C/T                  1/1                         1/1                         
  rs370974631   124,213,143                    AA/-                 0.93/NA                     1/NA                        
  rs200227426   124,213,671                    C/A                  0.96/NA                     0.99/NA                     
  rs201396317   124,213,674                    C/A                  0.96/NA                     0.99/NA                     
  rs199637836   124,213,677                    C/A                  0.96/NA                     0.99/NA                     
  rs11200634    124,213,680                    C/A                  0.96/NA                     0.99/NA                     
  rs75431719    124,213,688                    C/A                  0.96/NA                     0.99/NA                     
  rs10490924    124,214,448                    G/T                  Reference SNP               Reference SNP              22, 23, 24, 25, 26, 27, 28, 36, and additional 140 refs
  rs144224550   124,214,600                    \- /GT               1/NA                        1/NA                        
  rs36212731    124,214,976                    G/T                  0.99/1                      1/1                         
  rs36212732    124,215,198                    A/G                  1/1                         1/1                         
  rs36212733    124,215,211                    T/C                  1/1                         1/1                         
  rs3750848     124,215,315                    T/G                  1/1                         1/1                        29
  rs3750847     124,215,421                    C/T                  1/1                         1/1                        30
  rs3750846     124,215,565                    T/C                  1/1                         1/1                        1, 29
  rs566108895   124,216,823                    G/T                  0.91/NA                     0.99/NA                     
  rs3793917     124,219,275                    C/G                  0.99/0.98                   1/0.99                     29, 31, 32, 33
  rs3763764     124,220,061                    A/G                  0.98/0.98                   0.99/0.99                   
  rs11200638    124,220,544                    G/A                  0.98/0.9                    0.99/0.97                  17, 18, 19, 20, 21, 22, 23, and additional 100 refs
  rs1049331     124,221,270                    C/T                  0.97/0.96                   0.99/0.99                  34, 37
  rs2293870     124,221,276                    G/C,T                NA/0.9                      NA/0.95                    34, 38, 39
  rs2284665     124,226,630                    G/T                  0.96/0.94                   0.99/0.98                  35
  rs60401382    124,227,624                    C/T                  0.84/0.82                   0.98/0.97                   
  rs11200643    124,229,203                    C/T                  0.82/0.8                    0.96/0.94                   
  rs58077526    124,230,024                    A/C                  0.91/0.89                   0.96/0.95                   
  rs932275      124,231,464                    G/A                  0.93/0.89                   0.97/0.96                  29
  rs2142308     124,234,037                    G/C                  0.92/0.89                   0.97/0.96                   

The SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) is the reference SNP used to obtain r^2^ and D' values in both the HaploReg and LDlink websites. In the 1000 Genome project European population there are 34 polymorphisms, including [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=10490924), in linkage disequilibrium using the inclusion criterion r^2^ ≥0.8 \[[@r11],[@r12]\]. LDlink r^2^ refers to the strength of the association of the alleles at the queried SNP with [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924). LDlink D' measures linkage disequilibrium normalized for allele frequency. NA = Not Available.

![Diagram of the chromosome 10q26 region containing the *PLEKHA1*, *ARMS2*, and *HTRA1* genes, as well as the locations of the SNPs that have been associated with risk for AMD by published GWASs and genetic studies.](mv-v23-318-f1){#f1}

The three genes in 10q26 closest to the region of the AMD-associated SNPs are (centromeric to telomeric) *PLEKHA1*, *ARMS2*, and *HTRA1*. There is an intergenic region of about 22 kilobases between *PLEKHA1* and *ARMS2* and an intergenic region of about 5 kilobases between *ARMS2* and *HTRA1* ([Figure 1](#f1){ref-type="fig"}). The 30-kb AMD-risk haplotype stretches from the intergenic region between the *PLEKHA1* and *ARMS2* genes to the middle of the *HTRA1* gene.

The high-AMD-risk haplotype is associated with low expression of the *PLEKHA1* gene
-----------------------------------------------------------------------------------

The *PLEKHA1* gene is about 60 kb in length and its termination codon, which is at the gene's telomeric boundary, is about 12 kb from the centromeric boundary of the AMD-risk haplotype. *PLEKHA1* is detectably expressed in all 53 tissues in the GTEx database ([Table 2](#t2){ref-type="table"} and Appendix 1) with an average expression level of about 9.5 RPKM. In 32 tissues, the average *PLEKHA1* expression was lower in people with the high-AMD-risk haplotype defined by [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T, and the associated p values were below 0.05 in ten of those tissues ([Table 2](#t2){ref-type="table"} and Appendix 2). Other SNPs in the AMD haplotype showed similar results, which was expected because of their strong linkage disequilibrium (Appendix 2). The effect was most striking in ovarian tissue (effect size −0.43, p = 3.8 × 10^−5^ for [rs100490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924); [Figure 2](#f2){ref-type="fig"}). The effect appears to be semidominant with the expression level in heterozygotes falling between the TT and GG homozygotes. In the nine tissues that showed the opposite pattern (higher expression levels in people with the high-AMD-risk haplotype), the variation in mRNA levels among the genotypes was small and of no statistical significance, with all but one of the p values greater than 0.4. Thus, although the *PLEKHA1* gene is more than 22 kb away from [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) and about 12 kb from SNP [rs61871744](https://www.ncbi.nlm.nih.gov/snp/?term=rs61871744) that defines the centromeric boundary of the AMD-risk haplotype, the expression of this gene in many tissues is influenced by sequences within the haplotype.

###### The [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T allele is associated with low levels (negative effect sizes) of *PLEKHA1* gene expression in most tissues.

  **Tissue**                             **P-value**   **Effect Size**   **Expression (Mean RPKM)**   **Number samples**
  -------------------------------------- ------------- ----------------- ---------------------------- --------------------
  Brain - Nucleus accumbens (bg)         0.084         0.14              N/A                          93
  Stomach                                0.45          0.038             20.678                       170
  Brain - Caudate (basal ganglia)        0.57          0.033             188.491                      100
  Brain - Hypothalamus                   0.77          0.024             101.534                      81
  Heart - Left Ventricle                 0.73          0.023             21.246                       190
  Brain - Frontal Cortex (BA9)           0.8           0.016             116.963                      92
  Brain - Putamen (basal ganglia)        0.82          0.016             193.492                      82
  Brain --Ant. cingulate cortex (BA24)   0.82          0.013             141.737                      72
  Heart - Atrial Appendage               0.93          0.0077            30.707                       159
  Small Intestine - Terminal Ileum       0.97          −0.0038           21.23                        77
  Testis                                 0.92          −0.0069           12.333                       157
  Liver                                  0.8           −0.024            52.72                        97
  Skin - Sun Exposed (Lower leg)         0.44          −0.032            62.651                       302
  Muscle - Skeletal                      0.25          −0.041            6.046                        361
  Artery - Coronary                      0.62          −0.043            145.955                      118
  Whole Blood                            0.1           −0.046            1.153                        338
  Brain - Cerebellar Hemisphere          0.64          −0.052            28.95                        89
  Esophagus - Mucosa                     0.35          −0.053            14.493                       241
  Pituitary                              0.47          −0.067            105.377                      87
  Esophagus - Muscularis                 0.14          −0.072            53.302                       218
  Thyroid                                0.12          −0.074            42.25                        278
  Adipose - Visceral (Omentum)           0.067         −0.081            110.21                       185
  Skin -Not Sun Exposed (Suprapubic)     0.11          −0.084            60.731                       196
  Colon - Sigmoid                        0.31          −0.086            74.374                       124
  Adipose - Subcutaneous                 0.05          −0.088            126.917                      298
  Colon - Transverse                     0.12          −0.089            36.749                       169
  Breast - Mammary Tissue                0.15          −0.089            114.907                      183
  Lung                                   0.0069        −0.11             36.291                       278
  Artery - Aorta                         0.056         −0.11             268.567                      197
  Spleen                                 0.19          −0.14             26.428                       89
  Brain - Cortex                         0.032         −0.15             118.249                      96
  Pancreas                               0.051         −0.15             14.597                       149
  Artery - Tibial                        0.0013        −0.18             139.083                      285
  Brain - Hippocampus                    0.044         −0.18             129.512                      81
  Prostate                               0.11          −0.18             37.874                       87
  Adrenal Gland                          0.037         −0.21             36.181                       126
  Vagina                                 0.0068        −0.22             96.109                       79
  Uterus                                 0.083         −0.22             104.586                      70
  Nerve - Tibial                         1.40E-08      −0.25             99.2                         256
  Brain - Cerebellum                     0.003         −0.3              44.175                       103

![In the ovaries, women who are homozygous or heterozygous for the AMD-risk allele [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490929)-T have lower average *PLEKHA1* mRNA levels compared with homozygotes with the reference allele G. Error bars indicate the standard error of the mean. The sample size (n) in each group is indicated above each genotype.](mv-v23-318-f2){#f2}

The high-AMD-risk haplotype is associated with low expression of *ARMS2*
------------------------------------------------------------------------

The *ARMS2* transcriptional unit is about 2 kb and is completely contained within the 30-kb region containing the AMD-risk SNPs. In the GTEx transcriptome data set, *ARMS2* mRNA is not detected in 18 tissues and is at a low level in most of the other tissues, averaging only about 0.2 RPKM and never above 1.0 RPKM except testes that have a level of 3.0 RPKM ([Table 3](#t3){ref-type="table"} and Appendix 3). In the testes, homozygotes with the [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490929)-T allele (a marker of the high-AMD-risk haplotype) generally have lower *ARMS2* mRNA levels than homozygotes with the low-AMD-risk G allele (effect size −0.79, p = 7.5 × 10^−24^; [Figure 3](#f3){ref-type="fig"}). The effect appears to be semidominant with the expression level in heterozygotes falling between the TT and GG homozygotes. As expected because of strong linkage disequilibrium, another high-AMD-risk allele in the region ([rs1120638](https://www.ncbi.nlm.nih.gov/snp/?term=rs11200638)-A), which is in the same haplotype as the [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T allele, is also associated with a low *ARMS2* mRNA level in the testes (effect size −0.76, p = 8.3 × 10^−20^; Appendix 2). Eight other AMD-associated variants in this region that we evaluated are associated with a similarly low expression of *ARMS2* in the testes (Appendix 2).

###### The [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T allele is associated with low levels (negative effect sizes) of *ARMS2* gene expression in most tissues.

  **Tissue**                                  **P-Value**   **Effect Size**   **Expression (Mean RPKM)**   **Number Samples**
  ------------------------------------------- ------------- ----------------- ---------------------------- --------------------
  Brain - Anterior cingulate cortex (BA24)    0.95          0.012             N/A                          72
  Muscle - Skeletal                           0.98          0.0017            0                            361
  Brain - Caudate (basal ganglia)             0.93          −0.015            0.057                        100
  Nerve - Tibial                              0.71          −0.04             0.059                        256
  Liver                                       0.74          −0.048            0.099                        97
  Adipose - Subcutaneous                      0.49          −0.056            0.113                        298
  Brain - Frontal Cortex (BA9)                0.76          −0.063            0.079                        92
  Breast - Mammary Tissue                     0.51          −0.082            0.07                         183
  Colon - Transverse                          0.18          −0.12             0.054                        169
  Stomach                                     0.1           −0.15             0.036                        170
  Thyroid                                     0.086         −0.16             0.051                        278
  Pituitary                                   0.33          −0.16             0.382                        87
  Brain - Putamen (basal ganglia)             0.37          −0.17             0.06                         82
  Heart - Left Ventricle                      0.075         −0.18             0.055                        190
  Lung                                        0.098         −0.18             0.033                        278
  Prostate                                    0.35          −0.19             0.082                        87
  Adipose - Visceral (Omentum)                0.022         −0.2              0.116                        185
  Esophagus - Mucosa                          0.069         −0.2              0.136                        241
  Brain - Cortex                              0.24          −0.23             0.084                        96
  Brain - Hippocampus                         0.23          −0.24             0.075                        81
  Vagina                                      0.088         −0.25             N/A                          79
  Heart - Atrial Appendage                    0.042         −0.27             0.022                        159
  Artery - Tibial                             0.00041       −0.35             0.099                        285
  Ovary                                       0.014         −0.35             0.472                        85
  Colon - Sigmoid                             0.005         −0.4              0.152                        124
  Skin - Not Sun Exposed (Suprapubic)         0.0003        −0.41             0.115                        196
  Esophagus - Muscularis                      0.000063      −0.45             0.136                        218
  Small Intestine - Terminal Ileum            0.0079        −0.45             0.044                        77
  Skin - Sun Exposed (Lower leg)              7.00E-07      −0.46             N/A                          302
  Artery - Aorta                              0.00007       −0.47             0.109                        197
  Uterus                                      0.0049        −0.5              0.184                        70
  Brain - Nucleus accumbens (basal ganglia)   0.003         −0.54             0.05                         93
  Artery - Coronary                           5.50E-06      −0.56             0.094                        118
  Brain - Hypothalamus                        0.00019       −0.67             0.089                        81
  Testis                                      7.50E-24      −0.79             3.012                        157

![In the testes, men who are homozygous or heterozygous for the AMD-risk allele [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490929)-T have lower average *ARMS2* mRNA levels compared with homozygotes with the reference allele G. Error bars indicate the standard error of the mean. The sample size (n) in each group is indicated above each genotype.](mv-v23-318-f3){#f3}

Among tissues other than the testes, 34 express detectable but low levels of *ARMS2* and thus provide poor statistical power ([Table 3](#t3){ref-type="table"}). In 32 of the 34 tissues, the *ARMS2* transcript levels were numerically lower in homozygotes with the [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490929)-T allele compared with heterozygotes or G-allele homozygotes, a trend that is concordant with the results from the testes ([Table 3](#t3){ref-type="table"}). The difference in expression between people with the high-AMD-risk T allele versus the low-AMD-risk G allele reached p values less than or equal to 0.05 in 14 of the tissues, such as sun-exposed skin (p = 7.0 × 10^−7^) and coronary artery (p = 5.5 × 10^−6^). Analysis of the other SNPs in the AMD-risk haplotype that we evaluated showed a similar pattern (Appendix 2).

The high-AMD-risk haplotype is associated with high expression of the *HTRA1* gene
----------------------------------------------------------------------------------

The SNP [rs2142308](https://www.ncbi.nlm.nih.gov/snp/?term=rs2142308), which forms the telomeric boundary of the AMD-risk haplotype, is inside intron 1 of *HTRA1*. *HTRA1* mRNA is ubiquitously expressed with RPKM values ranging from 1 (whole blood) to 269 (the aorta) and averages about 400-fold higher than *ARMS2* and 8.5-fold higher than *PLEKHA1* (81.2 RPKM versus 0.2 or 9.5 RPKM, respectively; [Table 4](#t4){ref-type="table"} and Appendix 4). In 27 tissues, the average *HTRA1* expression was higher in people with the high-AMD-risk haplotype defined by [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T, and the effect was associated with p values of less than 0.05 in six of those tissues ([Table 4](#t4){ref-type="table"} and Appendix 2). The effect was most striking in the testes (effect size 0.4, p = 1.5 × 10^−7^ for [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924); [Figure 4](#f4){ref-type="fig"} and [Table 4](#t4){ref-type="table"}). In one tissue (prostate), the opposite association was observed with an effect size of −0.23 (p = 0.02). Analysis of the other SNPs in the AMD-risk haplotype that we evaluated showed a similar pattern in HTRA1 mRNA levels in human tissues (Appendix 2). In one tissue (prostate) the opposite association was observed with an effect size of -0.23 (p = 0.02) with [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924).

###### The [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T allele is associated with low levels (positive effect sizes) of *HTRA1* gene expression in most tissues.

  **Tissue**                                        **P-Value**   **Effect Size**   **Expression (Mean RPKM)**   **Number Samples**
  ------------------------------------------------- ------------- ----------------- ---------------------------- --------------------
  [Testis]{.ul}                                     1.50E-07      0.4               12.333                       157
  [Pituitary]{.ul}                                  0.016         0.28              105.377                      87
  [Artery - Coronary]{.ul}                          0.043         0.16              144.948                      118
  [Artery - Aorta]{.ul}                             0.017         0.13              268.567                      197
  [Liver]{.ul}                                      0.12          0.12              52.72                        97
  [Breast - Mammary Tissue]{.ul}                    0.074         0.11              114.907                      183
  [Whole Blood]{.ul}                                0.029         0.1               1.153                        338
  [Lung]{.ul}                                       0.032         0.098             36.291                       278
  [Adipose - Subcutaneous]{.ul}                     0.056         0.094             126.917                      298
  [Small Intestine - Terminal Ileum]{.ul}           0.24          0.093             21.23                        77
  [Vagina]{.ul}                                     0.12          0.09              96.109                       79
  [Adrenal Gland]{.ul}                              0.36          0.082             36.291                       126
  [Nerve - Tibial]{.ul}                             0.26          0.077             99.2                         256
  [Colon - Transverse]{.ul}                         0.074         0.066             36.749                       169
  [Spleen]{.ul}                                     0.45          0.06              26.428                       89
  [Brain - Hippocampus]{.ul}                        0.63          0.051             129.512                      81
  [Heart - Atrial Appendage]{.ul}                   0.44          0.043             30.707                       159
  [Thyroid]{.ul}                                    0.32          0.039             42.25                        278
  [Esophagus - Mucosa]{.ul}                         0.46          0.032             14.493                       241
  [Muscle - Skeletal]{.ul}                          0.34          0.026             6.046                        361
  [Skin - Sun Exposed (Lower leg)]{.ul}             0.64          0.019             62.815                       302
  [Artery - Tibial]{.ul}                            0.78          0.01              139.083                      285
  [Adipose - Visceral (Omentum)]{.ul}               0.86          0.0092            110.21                       185
  [Heart - Left Ventricle]{.ul}                     0.88          0.0084            21.246                       190
  [Brain - Nucleus accumbens (bg)]{.ul}             0.97          0.0036            132.309                      93
  [Pancreas]{.ul}                                   0.98          0.0024            14.597                       149
  [Ovary]{.ul}                                      0.99          0.0012            211.834                      85
  [Stomach]{.ul}                                    0.78          −0.012            20.678                       170
  [Brain - Hypothalamus]{.ul}                       0.83          −0.026            101.534                      81
  [Brain - Cortex]{.ul}                             0.68          −0.03             118.249                      96
  [Brain - Caudate (basal ganglia)]{.ul}            0.68          −0.037            188.491                      100
  [Brain - Anterior cingulate cortex (BA24)]{.ul}   0.29          −0.069            141.737                      72
  [Esophagus - Muscularis]{.ul}                     0.13          −0.081            53.302                       218
  [Colon - Sigmoid]{.ul}                            0.29          −0.089            74.374                       124
  [Brain - Frontal Cortex (BA9)]{.ul}               0.21          −0.092            116.804                      92
  [Brain - Cerebellum]{.ul}                         0.18          −0.099            44.175                       103
  [Skin - Not Sun Exposed (Suprapubic)]{.ul}        0.12          −0.1              60.731                       196
  [Brain - Putamen (basal ganglia)]{.ul}            0.18          −0.1              193.492                      82
  [Brain - Cerebellar Hemisphere]{.ul}              0.15          −0.12             28.95                        89
  [Uterus]{.ul}                                     0.073         −0.21             104.586                      70
  [Prostate]{.ul}                                   0.017         −0.23             37.874                       87

![In the testes, men who are homozygous or heterozygous for the AMD-risk allele [rs10490929](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490929)-T have higher average higher *HTRA1* mRNA levels compared with homozygotes with the reference allele G. Error bars indicate the standard error of the mean. The sample size (n) in each group is indicated above each genotype.](mv-v23-318-f4){#f4}

The high-AMD-risk haplotype has no detectable effect on the expression of distant genes
---------------------------------------------------------------------------------------

To test whether the high-AMD-risk haplotype could influence the expression of genes even more distant than *PLEKHA1*, *ARMS2*, or *HTRA1*, we examined the transcription of the 22 genes located within 1 megabase of the *PLEKHA1*-*ARMS2*-*HTRA1* cluster in all 44 human tissues in the GTEx database. Of the 22 genes, 16 were detectably transcribed in at least one tissue. There was no statistically significant association between alleles at the reference SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) and the expression of any of these 16 genes in any of the 44 tissues. In fact, searching through the entire transcriptomes of all 44 tissues in the GTEx database with the criterion of a false discovery rate (FDR) of less than or equal to 0.5, none of the AMD-associated SNPs appeared to be eQTLs for any gene on any chromosome except *PLEKHA1*, *ARMS2*, and *HTRA1* ([Table 5](#t5){ref-type="table"}). Thus, the 10q26 high-AMD-risk haplotype appears to affect only *PLEKHA1*, *ARMS2*, and *HTRA1*, and it is unlikely that the high-AMD-risk haplotype has a distant eQTL or inter-chromosome effect on gene expression.

###### Single tissue significant cis-eQTLs for AMD-associated SNPs [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924).

  **Gencode ID**       **Gene Symbol**   **P-Value**   **Effect Size**   **Tissue**
  -------------------- ----------------- ------------- ----------------- --------------------------------
  ENSG00000254636.1    ARMS2             7.50E-24      −0.79             Testis
  ENSG00000107679.10   PLEKHA1           1.40E-08      −0.25             Nerve - Tibial
  ENSG00000166033.7    HTRA1             1.50E-07      0.4               Testis
  ENSG00000254636.1    ARMS2             7.00E-07      −0.46             Skin - Sun Exposed (Lower leg)

The table provides the results from a search of GTEx for the entire list of genes that are influenced by the reference SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924) using the GTEx default criteria for significance. Note that only 3 genes appear, indicating that no other gene anywhere in chromosome 10q26 nor any gene in the GTEx database throughout the human genome is influenced by the reference SNP. Similar results appear for all of the 25 GTEx SNPs in the AMD-risk haplotype (data not shown), as expected since they are all in strong linkage disequilibrium.

Most SNPs from 10q26 that influence the expression of *PLEKHA1* and *ARMS2* have not been associated with AMD
-------------------------------------------------------------------------------------------------------------

Many more SNPs in 10q26 influence the expression of *PLEKHA1* and *ARMS2* than *HTRA1* ([Figure 5A](#f5){ref-type="fig"}). For example, the expression of *PLEKHA1* across 12 tissues is significantly influenced by more than 254 SNPs, with "significance" defined by the GTEx database significance criterion of an FDR of 5% or less. Of the 254 SNPs, 28 also affect the expression of *HTRA1*, while the remaining 226 SNPs affect the expression of *PLEKHA1* but not *HTRA1*. None of the 226 has been found to influence the risk for AMD. Only 25 of the 254 SNPs that influence the expression of *PLEKHA1* also modulate the risk for AMD, and all 25 are among those that modulate *HTRA1* expression. The expression of *ARMS2* in 13 tissues is influenced by 192 SNPs extending across 855 kb ([Figure 5A](#f5){ref-type="fig"} and Appendix 2). Of the 192 SNPs, 35 also affect the expression of *HTRA1*, while the remaining 157 affect the expression of *ARMS2* but not *HTRA1*. None of the 157 has been found to influence the risk for AMD. Only 25 of the 192 SNPs that influence the expression of *ARMS2* also modulate the risk for AMD, and all 25 are among those that modulate *HTRA1* expression. Thus, more than 85% of the SNPs that influence the expression of *ARMS2* and *PLEKHA1* are not associated with risk for AMD. Ninety-nine of these SNPs have high minor allele frequencies (higher than 0.2), and 35 have a high effect size (absolute value higher than 1; Appendix 2). Some of these SNPs were definitely included in published genome-wide association studies (GWASs). For example, 20 SNPs that affect *PLEKHA1* and *ARMS2* but not *HTRA1* are in the Illumina Human 610-Quad BeadChip used by Fritsch et al. who did not report an association with AMD with any of these SNPs \[[@r40]\]. It is likely that among the numerous, large GWASs conducted on patients with AMD, some of these SNPs would have been identified as influencing risk for AMD if they actually had an effect on risk for AMD.

![The locations of single nucleotide polymorphisms (SNPs) that influence the expression of *PLEKHA1*, *ARMS2*, or *HTRA1* (i.e., cis-expression quantitative trait loci (eQTLs)). **A**: The top of the figure shows the intron--exon structures of the *PLEKHA1*, *ARMS2*, and *HTRA1* genes. Under the schematic genome segment are three graphs with each graph showing the locations of SNPs that affect the mRNA expression (i.e., eQTLs) for each respective gene. The x-axis has the base pair locations, with the scale numbers at the bottom of the three graphs based on human genome reference GRCh37/hg19. The dots are colored so they correspond to panel B (green = *PLEKHA1*, blue = *ARMS2*, red = *HTRA1*). To be an eQTL on this graph, an SNP must meet the threshold for significance as calculated by the GTEx software (a false discovery rate of less than 0.5) in at least one tissue. The effect size (y-axis) is the maximum effect size across all tissues, with positive values meaning that the minor (alternative) allele is associated with higher expression. There are some eQTLs (75 for *PLEKHA1*, 44 for *ARMS2*, and four for *HTRA1*) off the ends of these graphs that are not included because of size limitations. **B**: Expanded view of the eQTLs in the region of the AMD-risk haplotype. The x-axis in this view is not linear. Black arrows point to the ten SNPs that have been reported in genome-wide association studies (GWASs) and genetic studies as associated with risk for AMD. Unfilled arrows are SNPs in strong linkage disequilibrium with the reported AMD-risk SNPs (linkage disequilibrium r^2^ \>0.8) and that therefore are highly likely to be associated with risk for AMD but have not been reported as such in GWASs, perhaps because they have not been included in those studies. Note that all AMD-risk SNPs are associated with high *HTRA1*, low *PLEKHA*1, and low *ARMS2* mRNA expression. Note also that there are 18 SNPs within the region of the AMD-risk haplotype in **B** and more than 100 that are away from it (shown in **A**) that affect the expression of *PLEKHA1* and *ARMS2* (denoted by SNPs with green or blue dots) but that have never been reported to influence risk for AMD. The location of the open chromatin region in the RPE with the highest DNase I sensitivity is indicated as a horizontal bar. Not shown is the ins/del polymorphism esv2663177 (del443/ins54) which is between [rs3750846](https://www.ncbi.nlm.nih.gov/snp/?term=rs3750846) and [rs3793917](https://www.ncbi.nlm.nih.gov/snp/?term=rs3793917).](mv-v23-318-f5){#f5}

For *HTRA1*, only 41 SNPs influence its expression. Thirty-four of these 41 SNPs are concentrated in the 30-kb AMD haplotype region, including all 25 SNPs in the AMD-risk haplotype ([Figure 5B](#f5){ref-type="fig"}). All AMD-risk SNPs that influence the expression of *PLEKHA1* or *ARMS2* also influence the expression of *HTRA1*.

Two AMD-risk SNPs alter predicted transcription factor binding sites
--------------------------------------------------------------------

The ENCODE database of open chromatin regions includes data from the RPE, a monolayer of cells that plays a key role in the pathogenesis of AMD. Within the 30-kb AMD-risk region, there are three DNase I hypersensitive sites in RPE cells ([Table 6](#t6){ref-type="table"}). We evaluated whether any of the 34 polymorphisms in the AMD-risk haplotype, including the 25 in the GTEx database and the nine additional polymorphisms in the LDlink database, were within the DNase I hypersensitive sites. The site with the most DNase I hypersensitivity is a 170-bp segment extending from chromosome 10 positions 124,215,021-124,215,190 ([Figure 5B](#f5){ref-type="fig"}). This site is 5.8 kb upstream of the transcription start site of *HTRA1* and within the intron of *ARMS2*. Using the transcription-factor-binding-motif-prediction software HOMER, PROMO, and RegulomeDB, we searched for consensus binding sequences for transcription factors in the open chromatin region that might include AMD-risk SNPs. The results implicated two AMD-risk SNPs, [rs36212732](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212732) and [rs36212733](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212733), which are 8 bp and 21 bp, respectively, away from the telomeric boundary of the hypersensitive site ([Figure 6](#f6){ref-type="fig"}). In comparison with the low-AMD-risk haplotype, the high-AMD-risk haplotype loses sites for transcription factors YY1, LHX2, LHX3, NKX6--1, ALX1, and ALX3, and it creates a site for the transcription factor c-MYB ([Figure 6](#f6){ref-type="fig"}). These transcription factors are expressed in human RPE cells \[[@r41],[@r42]\].

###### DNase I hypersensitive clusters at chromosome 10q26.13 in HRPEpiC\* and changes in transcription factor binding sites from low-AMD-risk reference alleles to high-AMD-risk alternate alleles.

  **Position**                 **Genomic size**   **Signal**   **SNPs in the AMD haplotype**      **Transcription factor motif in reference allele**   **Transcription factor motif in alternate allele**
  ---------------------------- ------------------ ------------ ---------------------------------- ---------------------------------------------------- ----------------------------------------------------
  chr10:124215021--124215190   170                163          rs36212731 rs36212732 rs36212733   YY1, LHX2, LHX3, NKX6--1, ALX1, ALX3                 c-MYB
  chr10:124220906--124222950   2045               12           rs1049331 rs2293870                                                                      
  chr10:124228506--124228935   430                13                                                                                                    

\* HRPEpiC: Human Retinal Pigment Epithelial Cells

![Changes in predicted transcription factor binding sites by SNPs associated with risk for AMD. The single nucleotide polymorphisms (SNPs) [rs36212732](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212732) and [rs36212733](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212733) are 8--21 bp away from the telomeric boundary of an open chromatin region with the high DNase I sensitivity in RPE cells. The low-AMD-risk haplotype has the base "A" at [rs36212732](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212732) and the base "T" at [rs36212733](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212733), while the high-AMD-risk allele has the bases "G" and "C" at the respective locations. In comparison with the low-AMD-risk haplotype, the high-AMD-risk haplotype has a predicted reduction in the binding of the transcription factor YY-1, LHX2, LHX3, NKX6--1, ALX1, and ALX3, and a predicted increase in the binding of the factor c-MYB, as predicted by the software HOMER, PROMO, and RegulomeDB. The consensus YY-1, LHX2, LHX3, NKX6--1, ALX1, ALX3, and c-MYB binding sequences are from the JASPAR website.](mv-v23-318-f6){#f6}

The other two open chromatin sites in this region are less than one tenth as sensitive to DNase I ([Table 6](#t6){ref-type="table"}). One extends from 124,220,906-124,222,950 and contains two AMD-risk SNPs ([rs1049331](https://www.ncbi.nlm.nih.gov/snp/?term=rs1049331) and [rs2293870](https://www.ncbi.nlm.nih.gov/snp/?term=rs2293870)), but these polymorphisms do not affect any potential transcription factor binding sites according to the HOMER, PROMO, and RegulomeDB programs. The other open chromatin site extends from 124,228,506-124,228,935 and has no AMD-associated SNPs within or nearby.

Discussion
==========

We used the GTEx genotype-tissue expression database to explore the effects of SNPs that influence the susceptibility for AMD on the expression of nearby genes in the 10q26 *ARMS2*-*HTRA1* region. The AMD-risk alleles at ten SNPs in this region are in strong linkage disequilibrium, and there are 24 additional nearby SNPs or insertion-deletion polymorphisms that are similarly correlated, 15 of which are in the GTEx database. Based on results from 25 of these SNPs in the GTEx database, high-AMD-risk alleles are associated with lower levels of *ARMS2* and *PLEKHA1* mRNA and higher levels of *HTRA1* mRNA than low-AMD-risk alleles in many human tissues. The AMD-risk SNPS do not influence the level of expression of any other gene in this region or anywhere in the human genome with statistical significance after adjustment for the multiple comparisons. Thus, if the risk for AMD conferred by this region is due to variation in gene expression (rather than a change in the transcribed protein), then the risk is due to variation in the expression of one of these three genes.

The GTEx data additionally provide evidence that variations in *ARMS2* and *PLEKHA1* expression are less likely than *HTRA1* to influence risk for AMD. Hundreds of additional SNPs in this region influence the expression of *ARMS2* and *PLEKHA1* but not *HTRA1*. None of those additional SNPs has been associated with the risk for AMD in any published human genetics study although some of these SNPs were included in those studies. However, most of the SNPs (25/41) that influence *HTRA1* expression are associated with risk for AMD either from direct evidence from GWASs or because the SNPs are highly correlated with directly implicated SNPs. Two other items provide further support for disregarding *ARMS2* as an AMD-susceptibility gene: 1) *ARMS2* mRNA and protein are expressed at extremely low levels in eye tissues \[[@r9],[@r18]\]; and 2) human genetics studies of AMD indicate that a specific SNP that creates a nonsense mutation (Arg38End) in *ARMS2* is associated with low risk for AMD \[[@r5],[@r10],[@r43]-[@r45]\]. In short, *HTRA1* is the most likely candidate gene for risk for AMD in this region, and if so, elevated expression of *HTRA1* likely increases risk for AMD.

The present analysis was based heavily on the idea that the level of expression of a gene on 10q26 determines risk for AMD. An alternative explanation is that there is a change in the primary structure of an encoded protein. Only one such polymorphism is known among the three candidates. It involves the reference SNP [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924), which is a missense polymorphism (Ala69Ser) that affects the *ARMS2* coding sequence. The Ala69 *ARMS2* allele corresponds to low risk for AMD and high *ARMS2* expression while the Ser69 allele corresponds to high risk for AMD and low *ARMS2* expression. Evidence against this polymorphism as the basis for risk for AMD is as follows. If expression of Ala69-*ARMS2* protects against AMD, one would expect that loss of *ARMS2* expression would always be associated with elevated risk for AMD. However, a separate *ARMS2* variant, the nonsense change Arg38End, would be expected to produce no functional *ARMS2*, yet the variant has been found to confer low risk for AMD. The possibility remains that the Ser69 allele promotes the development of AMD because of some toxic effect of the Ser69-*ARMS2* protein. This mechanism remains a possibility, but we feel it is unlikely because the Ser69 variant is expressed at low levels across all evaluated tissues. In particular, a recent report showed that the Ser69-*ARMS2* protein could not be detected in monocytes from patients carrying the homozygous risk for AMD [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T variant \[[@r46]\].

Support for *HTRA1* as the risk for AMD factor comes from reports of two- to threefold higher *HTRA1* expression in eyes with AMD \[[@r10],[@r17],[@r47]-[@r51]\], although other groups report no effect \[[@r28],[@r45],[@r52]-[@r55]\]. Some support for low *HTRA1* expression protecting against AMD comes from patients who lack *HTRA1* due to recessive, null mutations. Such patients have cerebral arteries with small lumens and thick walls with reduplicated elastic laminas. No AMD has been observed in such patients \[[@r56]\].

There are weaknesses in the present analysis. Although the GTEx database includes six tissues with a strong correlation between high-AMD-risk SNP alleles and higher *HTRA1* expression level and 21 others have a trend in the same direction, one tissue (prostate) showed a correlation in the opposite direction. It would be ideal to have ocular tissues for evaluation, but unfortunately, no data from ocular tissues are available in the GTEx database. It is still unclear to what extent systemic factors influence one's risk for AMD \[[@r57]\]. It is conceivable that variation in the systemic expression of *HTRA1*, not its local ocular expression, is responsible for increasing the risk for AMD.

A potential mechanism for the variation in the expression *HTRA1* due to the AMD-risk haplotype involves an open chromatin (DNase I-sensitive) region in the RPE that we found in the ENCODE database. This region is 8--21 bp away from the AMD-risk SNPs [rs36212732](https://www.ncbi.nlm.nih.gov/snp/?term=rs3621273) and [rs36212733](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212733). Specifically, the change from the low-AMD-risk allele to the high-AMD-risk allele switches transcription factor binding from YY-1, LHX2, LHX3, ALX1, ALX3, or NKX6--1 to c-MYB ([Figure 6](#f6){ref-type="fig"}).

A recently published evaluation of the *ARMS2*-*HTRA1* region provides additional evidence for the importance of the open chromatin region and the SNPs near it that potentially affect transcription factor binding sites \[[@r58]\]. Based on 33,000 AMD cases and controls, the interval most likely responsible for risk for AMD was narrowed down to a 7136-bp segment bounded by SNPs [rs11200630](https://www.ncbi.nlm.nih.gov/snp/?term=rs11200630) and esv2663177. This interval is within the AMD haplotype we defined and contains 13 of the 25 SNPs. This interval includes the open chromatin region we uncovered, as well as the SNPs [rs36212732](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212732) and [rs36212733](https://www.ncbi.nlm.nih.gov/snp/?term=rs36212733) that affect transcription factor binding sites. It is conceivable that variation in these two SNPs is the fundamental cause for risk for AMD in 10q26 and that the changes in transcription factor affinity mediated by the SNP alleles cause the variation in the expression of the *HTRA1* gene located 5.8 kb away.

There are other possible mechanisms for the variation in the expression *HTRA1* or other genes due to the AMD-risk haplotype, three of which are the following. 1) AMD-risk SNPs, such as [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924), are in strong genetic linkage disequilibrium with the insertion/deletion polymorphism del443ins54 in the 3′ untranslated region of *ARMS* mRNA \[[@r29]\]. It is possible that the del443ins54 polymorphism introduces a conformational change in chromatin thus affecting the expression of genes in 10q26. However, the recently reported minimal region responsible for risk for AMD does not include this polymorphism, making it unlikely that it modulates risk for AMD \[[@r58]\]. 2) The reported pattern of DNA methylation in the promoter region of *ARMS2* correlates with the risk for AMD allele [rs10490924](https://www.ncbi.nlm.nih.gov/snp/?term=rs10490924)-T \[[@r59]\]. However, the variation in methylation would more likely affect the expression of *ARMS2* rather than *HTRA1* or *PLEKHA1*. 3) It is possible that transcriptional activity of the *ARMS2* or *PLEKHA1* genes might interfere with transcription of the nearby *HTRA1*. Chimeric transcripts starting from *PLEKHA1* and ending in *ARMS2* were recently reported \[[@r5]\]. The reduction in *ARMS2* and *PLEKHA1* transcription by the high-AMD-risk variants might consequently allow more *HTRA1* mRNA to be transcribed. This indirect effect on *HTRA1* gene expression may explain why fewer tissues with increased *HTRA1* gene expression reached statistical significance compared to *ARMS2* in the GTEx database analysis.
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